Business
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER’ clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER’ clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024\nPURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, supports Lewy Body Dementia Awareness Month and the critical need for more attention, research, and treatments for people with dementia with Lewy bodies (DLB). DLB is the second most common form of progressive dementia, affecting approximately 1.4 million people in the U.S., with no approved treatments available. DLB is caused by the buildup of a protein called alpha-synuclein, which forms deposits called Lewy bodies inside neurons. Over time, these deposits interfere with normal cellular functions, causing a progressive decline in cognitive and motor skills. Symptoms of DLB vary among patients and fluctuate in intensity, making it challenging to diagnose and manage. These symptoms include impaired cognition and mental organization, visual hallucinations, REM sleep behavior disorder, and movement issues similar to Parkinson’s disease. \"Lewy Body Dementia Awareness Month is an important opportunity to raise awareness of this underdiagnosed but prevalent condition that can be devastating for patients and their loved ones,\" said Lisa Ricciardi, CEO of Cognition Therapeutics. \"At Cognition, we are committed to developing new treatments for neurodegenerative diseases like DLB, and believe our lead candidate, CT1812, has the potential to address the complex pathology driving this disease.\" Cognition Therapeutics partnered with experts at the Lewy Body Dementia Association (LBDA) and the University of Miami Miller School of Medicine to design the Phase 2 SHIMMER trial, which has enrolled 130 patients with mild-to-moderate DLB at centers of excellence across the United States. Topline results, which are anticipated later this year, are expected to provide insights into this patient population and the potential therapeutic impact of CT1812 on the constellation of symptoms that affect DLB patients. “The DLB community will be convening at the first Externally Led Patient-Focused Drug Development (EL-PFDD) Meeting* on October 15, 2024. During the meeting, patients and ...